These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 12113647)

  • 1. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis.
    Reitamo S; Remitz A; Kyllönen H; Saarikko J
    Am J Clin Dermatol; 2002; 3(6):381-8. PubMed ID: 12113647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on topical pimecrolimus in atopic dermatitis.
    Wellington K; Jarvis B
    Am J Clin Dermatol; 2002; 3(6):435-8. PubMed ID: 12113651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
    Breuer K; Werfel T; Kapp A
    Am J Clin Dermatol; 2005; 6(2):65-77. PubMed ID: 15799678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.
    Ashcroft DM; Dimmock P; Garside R; Stein K; Williams HC
    BMJ; 2005 Mar; 330(7490):516. PubMed ID: 15731121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.
    Wellington K; Jarvis B
    Drugs; 2002; 62(5):817-40. PubMed ID: 11929333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy.
    Werfel T
    J Dtsch Dermatol Ges; 2009 Sep; 7(9):739-42. PubMed ID: 19650820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pimecrolimus: a review.
    Gupta AK; Chow M
    J Eur Acad Dermatol Venereol; 2003 Sep; 17(5):493-503. PubMed ID: 12941081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
    Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
    de Bruin-Weller MS; Bruijnzeel-Koomen CA
    Ned Tijdschr Geneeskd; 2005 May; 149(20):1096-100. PubMed ID: 15932135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants.
    Luger T; Boguniewicz M; Carr W; Cork M; Deleuran M; Eichenfield L; Eigenmann P; Fölster-Holst R; Gelmetti C; Gollnick H; Hamelmann E; Hebert AA; Muraro A; Oranje AP; Paller AS; Paul C; Puig L; Ring J; Siegfried E; Spergel JM; Stingl G; Taieb A; Torrelo A; Werfel T; Wahn U
    Pediatr Allergy Immunol; 2015 Jun; 26(4):306-15. PubMed ID: 25557211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases.
    Hebert AA; Warken KA; Cherill R
    Semin Cutan Med Surg; 2001 Dec; 20(4):260-7. PubMed ID: 11770913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety of topical tacrolimus and pimecrolimus in children with atopic dermatitis].
    Rodríguez Orozco AR; Ruiz Reyes H; Marín Hernández D
    Rev Alerg Mex; 2005; 52(4):171-6. PubMed ID: 16268186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases.
    Bornhövd EC; Burgdorf WH; Wollenberg A
    Curr Opin Investig Drugs; 2002 May; 3(5):708-12. PubMed ID: 12090543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
    Hoetzenecker W; Ecker R; Kopp T; Stuetz A; Stingl G; Elbe-Bürger A
    J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm.
    Luger T; De Raeve L; Gelmetti C; Kakourou T; Katsarou A; Lambert J; Morren MA; Oranje A; Ruer M; Serdaroglu S; Torrelo A; Werfel T
    Eur J Dermatol; 2013; 23(6):758-66. PubMed ID: 24185493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
    Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
    Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation.
    Garside R; Stein K; Castelnuovo E; Pitt M; Ashcroft D; Dimmock P; Payne L
    Health Technol Assess; 2005 Jul; 9(29):iii, xi-xiii,1-230. PubMed ID: 16022804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atopic dermatitis: a new treatment paradigm using pimecrolimus.
    Weinberg JM; Bowerman JG; Brown SM; Gerstein D; Kane KS; Selevan J; Virdee S
    J Drugs Dermatol; 2003 Apr; 2(2):131-40. PubMed ID: 12852364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimecrolimus: a review of its use in atopic dermatitis.
    Wellington K; Noble S
    Am J Clin Dermatol; 2004; 5(6):479-95. PubMed ID: 15663345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.